These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15320808)

  • 21. The in vitro pharmacological profile of KR31080, a nonpeptide AT1 receptor antagonist.
    Hong KW; Kim CD; Lee SH; Yoo SE
    Fundam Clin Pharmacol; 1998; 12(1):64-9. PubMed ID: 9523186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells.
    Le MT; De Backer JP; Hunyady L; Vanderheyden PM; Vauquelin G
    Eur J Pharmacol; 2005 Apr; 513(1-2):35-45. PubMed ID: 15878707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.
    Wienen W; Hauel N; Van Meel JC; Narr B; Ries U; Entzeroth M
    Br J Pharmacol; 1993 Sep; 110(1):245-52. PubMed ID: 8220885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?
    Vanderheyden PM; Fierens FL; Vauquelin G
    Biochem Pharmacol; 2000 Dec; 60(11):1557-63. PubMed ID: 11077037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional and binding studies of insurmountable antagonism of 606A, a novel AT1-receptor antagonist in rabbit tissues.
    Kurosawa Y; Minami K; Hashimoto Y; Narita H
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):132-8. PubMed ID: 10413079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
    Maillard MP; Perregaux C; Centeno C; Stangier J; Wienen W; Brunner HR; Burnier M
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1089-95. PubMed ID: 12183667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists.
    Fierens FL; Vanderheyden PM; Gáborik Z; Minh TL; Backer JP; Hunyady L; Ijzerman A; Vauquelin G
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):283-8. PubMed ID: 11881039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ca2+]i and PKC-alpha are involved in the inhibitory effects of Ib, a novel nonpeptide AngiotensinII subtype AT1 receptor antagonist, on AngiotensinII-induced vascular contraction in vitro.
    Wang Y; Wang W; Wang Q; Wu J; Xu J; Wu X
    Biochem Biophys Res Commun; 2007 Dec; 364(1):118-23. PubMed ID: 17931598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological significance of the interplay between angiotensin receptors: MAS receptors as putative final mediators of the effects elicited by angiotensin AT1 receptors antagonists.
    Pernomian L; Pernomian L; Gomes MS; da Silva CH
    Eur J Pharmacol; 2015 Dec; 769():143-6. PubMed ID: 26548625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities.
    Saavedra JM
    Cell Mol Neurobiol; 2005 Jun; 25(3-4):485-512. PubMed ID: 16075377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.
    Le MT; Pugsley MK; Vauquelin G; Van Liefde I
    Br J Pharmacol; 2007 Aug; 151(7):952-62. PubMed ID: 17572702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss-of-function polymorphic variants of the human angiotensin II type 1 receptor.
    Hansen JL; Haunsø S; Brann MR; Sheikh SP; Weiner DM
    Mol Pharmacol; 2004 Mar; 65(3):770-7. PubMed ID: 14978256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells.
    Fierens F; Vanderheyden PM; De Backer JP; Vauquelin G
    Eur J Pharmacol; 1999 Feb; 367(2-3):413-22. PubMed ID: 10079018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The two-state model of antagonist-AT1 receptor interaction: an hypothesis defended but not tested.
    Lew MJ; Ziogas J
    Biochem Pharmacol; 2004 Feb; 67(3):397-9. PubMed ID: 15037191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.
    Ojima M; Inada Y; Shibouta Y; Wada T; Sanada T; Kubo K; Nishikawa K
    Eur J Pharmacol; 1997 Jan; 319(1):137-46. PubMed ID: 9030909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
    Berellini G; Cruciani G; Mannhold R
    J Med Chem; 2005 Jun; 48(13):4389-99. PubMed ID: 15974591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding.
    Saavedra JM; Armando I; Bregonzio C; Juorio A; Macova M; Pavel J; Sanchez-Lemus E
    Neuropsychopharmacology; 2006 Jun; 31(6):1123-34. PubMed ID: 16205776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.
    Zhang J; Wang JL; Yu WF; Zhou ZM; Tao WC; Wang YC; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
    Eur J Med Chem; 2013 Nov; 69():44-54. PubMed ID: 24007859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174).
    Morsing U Brandt-Eliasson L Renberg T Abrahamsson P
    Blood Press; 2000; 9(sup1):50-51. PubMed ID: 28425810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.